Epidemiology and Susceptibility Profiles of ST131-025b Escherichia coli Detected Among Cephalosporin- and/or Carbapenem-Resistant Isolates Collected in United States Hospitals

Sujata Bhavnani², Paul G. Ambrose²

¹JMI Laboratories, North Liberty, Iowa; ²Bravos Biosciences, Institute for Clinical Pharmacodynamics (ICPD), Schenectady, New York

Introduction

- The ST131 *E. coli* clone has spread across numerous countries in Asia, Europe, and North America and has been identified as an endemic organism that colonizes humans and causes human infections.
- These extra-intestinal *E. coli* (ExPEC) isolates belong to the phylogroup B2 and exhibit true virulence factors, including adhesions, capsules, invasins, lipopolysaccharides, proteases, and toxins.
- Most ST131 E. coli exhibit serotype 025b, which emerged as a fluoroquinolone resistance lineage that later acquired *bla*_{CTX-M-15}, conferring resistance to cephalosporins as well as other resistance genes.
- We evaluated the prevalence of ST131 and the antigen O25b among the E. coli isolates collected in US hospitals during 2017 and 2018 and analyzed the susceptibility patterns of the isolates that belonged to these groups.

Materials and Methods

- A total of 6,768 *E. coli* isolates were recovered from documented infections in 74 US hospitals during 2017 and 2018 according to a common surveillance design.
- All isolates were tested for antimicrobial susceptibility using broth microdilution methodology per CLSI M07 (2018) guidelines.
- MIC values were validated by concurrently testing CLSI-recommended M100 (2021) quality control (QC) reference strains.
- QC ranges for tested reference strains were approved or published by CLSI in the M100 (2021).
- All categorical interpretations used were published by CLSI in the M100 (2021) or were from the US Food and Drug Administration criteria for tigecycline.
- A total of 1,154 *E. coli* isolates were submitted to WGS and analysis, including: - Isolates displaying MIC values $\geq 2 \text{ mg/L}$ for at least 2 of the following β -lactams: ceftazidime, ceftriaxone, aztreonam, or cefepime and
- Isolates displaying MIC values $\geq 2 \text{ mg/L}$ for imipenem and/or meropenem.
- The housekeeping genes adk, fumC, gyrB, icd, mdh, purA, and recA were analyzed to detect ST131 and a single loci variant (SLV; 1 allele difference).
- ST131 and the SLV were evaluated for the presence of the O25b antigen using the EcOH database, the SRST2 software package, and by submitting a de novo assembly of quality-trimmed WGS reads to SerotypeFinder 2.0.
- The SerotypeFinder database compared sequences to wzx, wzy, wzm, and wzt for O-groups and filC, fikA, flmA, flnA, and fllA for H-types.
- If no O-antigen was observed in the *in silico* search, the isolate was submitted to a PCR reaction that was specific for O25b antigen, as described elsewhere.
- PCR also was used if there was disagreement between the *in silico* and WGS approaches.

Results

- A total of 47.8% of the 1,154 sequenced *E. coli* isolates were collected from urinary tract infections (552 isolates).
- The remaining isolates were recovered from bloodstream infections (257 isolates), isolates deemed as cause of pneumonia in hospitalized patients (159 isolates), skin/ soft tissue infections (115 isolates), and intra-abdominal infections (71 isolates). – 65 isolates that caused bloodstream infections had a primary source from urinary tract infections.
- IDWEEK 2021, September 29–October 3, 2021

Mariana Castanheira¹, Timothy B. Doyle¹, Andrew P. Davis¹, Valerie Kantro¹, Christopher Rubino²,

- Among 1,154 *E. coli* isolates, 627 belonged to ST131 or were SLVs that contained 1 allele of the MLST scheme difference with ST131 (Figure 1). – ST131 and SLV (ST131 herein) isolates were similarly distributed in 2017 and 2018. In 2017, 324 (52.0%) isolates were identified. In 2018, 303 (56.1%)
- isolates were identified.
- Among the US Census Bureau divisions, the occurrence of ST131 was lowest in the Mountain region (37.9%) and highest in the Mid-Atlantic (60.4%; Figure 2).
- A total of 586 *E. coli* isolates belonged to the O25b serotype, which corresponded to 93.5% of the ST131 isolates and 50.8% of the sequenced isolates (Figure 1). - Serotype 016 was detected in 40 isolates and a variant of 0153 was detected in 1 isolate of the 627 isolates evaluated.
- The prevalence of ST131-025b *E. coli* in the US Census Divisions ranged from 36.2% to 58.7% among the sequenced isolates.
- The highest occurrence of ST131-025b was in isolates from the South Atlantic region (Figure 2).
- ST131 *E. coli* isolates were considerably more resistant compared to the isolates that did not belong to the ST131 clade (Figure 3).
- Ceftriaxone, cefepime, the fluoroquinolones, tobramycin, and trimethoprimsulfamethoxazole had \geq 5% (range 6.1% to 35.8%) higher resistance rates in the ST131 group when compared to the non-ST131 group.
- ST131 (49.0%) and ST131-025b (51.5%) isolates had higher multidrug resistant (MDR; resistant to \geq 3 antimicrobial classes) rates compared to all *E. coli* isolates (7.3%), sequenced isolates (41.4%), and isolates that did not carry these traits (32.4% for non-ST131 and 12.2% for non-O25b; Figure 4).

Conclusions

- This study highlights the widespread distribution of ST131-025b E. coli in the US hospitals and documents the high resistance rates among these isolates, including multidrug resistance.
- Monitoring *E. coli* 025b-ST131 is critical as it can cause severe infections and there are limited treatment options active against these isolates.

Acknowledgements

This study was sponsored by Bravos Biosciences.

References

Banerjee R, Johnson JR (2014). A new clone sweeps clean: the enigmatic emergence of Escherichia coli sequence type 131. Antimicrob Agents Chemother 58: 4997-5004. Clermont O, Dhanji H, Upton M, et al. (2009). Rapid detection of the 025b-ST131 clone of Escherichia coli encompassing the CTX-M-15-producing strains. J Antimicrob Chemother 64: 274-277. Clinical and Laboratory Standards Institute (2018). M07ED11. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: eleventh edition. Wayne, PA: CLSI. Clinical and Laboratory Standards Institute (2021). M100Ed31. Performance standards for antimicrobial susceptibility testing: 31st informational supplement. Wayne, PA: CLSI.

Mendes RE, Jones RN, Woosley LN, et al. (2019). Application of next-generation sequencing for characterization of surveillance and clinical trial isolates: Analysis of the distribution of β-lactamase resistance genes and lineage background in the United States. Open Forum Infect Dis 6: S69-S78.

Nicolas-Chanoine MH, Bertrand X, Madec JY (2014). Escherichia coli ST131, an intriguing clonal group. Clin Microbiol Rev 27: 543-574.

Figure 1. Prevalence of ST131 Escherichia coli isolates and O serotypes collected from US hospitals during 2017 and 2018

Figure 2. Distribution of ST131 Escherichia coli isolates across the US **Census Divisions**




Figure 3. Activity of antimicrobial agents tested against ST131 Escherichia coli isolates collected from US hospitals during 2017 and 2018





Figure 4. Comparison of the prevalence of MDR (resistant to \geq 3 antimicrobial classes) isolates among analyzed Escherichia coli isolates



Contact

Mariana Castanheira JMI Laboratories 345 Beaver Kreek Centre, Suite A North Liberty, IA 52317 Phone: (319) 665-3370 ext 217 Fax: (319) 665-3371 Email: mariana-castanheira@jmilabs.com



To obtain a PDF of this poster: Scan the QR code or visit https:// www.jmilabs.com/data/posters /IDWeek2021_ST131-025bEcoli.pdf Charges may apply. No personal information is stored.